bladder cancer

bladder cancer
Name	Bladder cancer
Field	Oncology, Urology
Symptoms	Hematuria, dysuria, pelvic pain
Complications	Metastasis, renal failure, recurrence
Onset	Typically age >50 years
Causes	Smoking, occupational exposures
Risks	Age, male sex, chronic cystitis, schistosomiasis
Diagnosis	Cystoscopy, imaging, urine cytology
Treatment	Transurethral resection, intravesical therapy, cystectomy, chemotherapy, immunotherapy
Frequency	Varies by region; common in developed countries

bladder cancer Bladder cancer is a neoplasm arising from the urothelial lining of the urinary bladder, most often presenting with painless visible hematuria. It is commonly managed at the intersection of Urology, Oncology, and Pathology and has strong epidemiological links to tobacco exposure and industrial carcinogens. Management ranges from endoscopic resection to radical cystectomy and systemic therapy, involving institutions such as National Cancer Institute, Mayo Clinic, and major cancer centers worldwide.

Signs and symptoms

Patients typically present with visible or microscopic hematuria and may report irritative voiding symptoms such as urgency, frequency, and dysuria, leading them to seek care at facilities like Johns Hopkins Hospital or Cleveland Clinic. Advanced disease can produce pelvic pain, flank pain from hydronephrosis, or systemic manifestations including weight loss and anorexia seen in referrals to Memorial Sloan Kettering Cancer Center or during multidisciplinary tumor board reviews at MD Anderson Cancer Center. Paraneoplastic syndromes and venous thromboembolism may prompt consultation with services at Mayo Clinic or regional oncology units following diagnostic imaging.

Causes and risk factors

Tobacco smoking is the single largest modifiable risk factor, identified in cohort studies from institutions including Harvard School of Public Health and Imperial College London. Occupational exposure to aromatic amines in industries associated with companies historically linked to industrial carcinogens prompted regulatory action by agencies like Occupational Safety and Health Administration and research by International Agency for Research on Cancer. Chronic bladder inflammation from recurrent urinary tract infections or long-term indwelling catheters is recognized in case series from tertiary centers such as UCL Hospitals and registries managed by SEER Program. Endemic infection with Schistosoma haematobium in regions studied by World Health Organization increases risk of squamous cell variants, with population data reported by Centers for Disease Control and Prevention and national health ministries.

Pathophysiology and classification

Most tumors arise from urothelial cells and are categorized along staging systems promulgated by American Joint Committee on Cancer and histologic grading schemes developed by panels including members of World Health Organization. Molecular alterations described in publications from The Cancer Genome Atlas and laboratories at Dana-Farber Cancer Institute include mutations in TP53, FGFR3, and alterations in chromatin-modifying genes reported by consortia at Broad Institute. The clinical taxonomy separates non–muscle-invasive disease managed by transurethral approaches from muscle-invasive disease often requiring radical treatment, a distinction used in guidelines from European Association of Urology and National Comprehensive Cancer Network.

Diagnosis

Initial evaluation often includes urinalysis and urine cytology, with cytopathology protocols refined at centers like Mayo Clinic and Johns Hopkins Hospital. Cystoscopy, including white-light and enhanced techniques such as blue light or narrow-band imaging, is routine in operating rooms at Guy's and St Thomas' NHS Foundation Trust and academic hospitals worldwide. Imaging modalities—contrast-enhanced CT urography and MRI—are interpreted following standards from radiology departments at Massachusetts General Hospital and Karolinska University Hospital. Histopathologic assessment of transurethral resection specimens uses grading criteria endorsed by World Health Organization committees and staging by American Joint Committee on Cancer.

Treatment

Management algorithms, adopted by National Comprehensive Cancer Network and European Association of Urology, span endoscopic resection with intravesical therapy (e.g., Bacillus Calmette–Guérin) often administered per protocols from Institut Gustave Roussy and Vall d'Hebron Institute of Oncology. Muscle-invasive disease may require radical cystectomy with urinary diversion techniques performed at high-volume centers such as Memorial Sloan Kettering Cancer Center and Mayo Clinic, often combined with neoadjuvant cisplatin-based chemotherapy informed by trials conducted by cooperative groups like European Organisation for Research and Treatment of Cancer and North Central Cancer Treatment Group. Immune checkpoint inhibitors approved following pivotal trials at institutions including Dana-Farber Cancer Institute and pharmaceutical collaborations have expanded options for metastatic disease; targeted therapies against FGFR alterations were developed in industry-linked studies and academic partnerships with centers such as Dana-Farber Cancer Institute.

Prognosis and epidemiology

Prognosis depends on stage and grade; non–muscle-invasive disease has high recurrence but favorable survival when treated per guidelines from European Association of Urology, while muscle-invasive and metastatic disease carry worse outcomes documented in population analyses by SEER Program and national cancer registries like Cancer Research UK. Incidence is higher in regions with elevated tobacco use and industrial exposures, trends tracked by World Health Organization and Global Burden of Disease studies. Survival improvements over decades reflect advances from cooperative trials coordinated by groups such as Southwest Oncology Group and implementation of multidisciplinary care at centers like MD Anderson Cancer Center.

Prevention and screening

Primary prevention emphasizes tobacco control policies advocated by World Health Organization Framework Convention and occupational exposure limits implemented by Occupational Safety and Health Administration and national regulators. Vaccination and control programs against Schistosoma haematobium in endemic areas run by World Health Organization and partner NGOs reduce squamous cell carcinoma risk. There is no consensus population screening program endorsed by U.S. Preventive Services Task Force or National Comprehensive Cancer Network; targeted surveillance for high-risk cohorts is performed at specialist centers including University College London Hospitals and national referral hospitals, often using cystoscopy and urine markers in longitudinal follow-up.

Category:Urologic neoplasms